Adverse effects of topical photodynamic therapy

Photodermatology Photoimmunology and Photomedicine

Volumn 27, Issue 3, 2011, Pages 116-130

  Ibbotson, Sally Helen ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

Adverse effects; Pain; Photodynamic therapy

Indexed keywords

AMINOLEVULINIC ACID; AMINOLEVULINIC ACID METHYL ESTER;

CARCINOGENICITY; COOLING; DERMATITIS; DYSPLASIA; HUMAN; MEDLINE; NAIL DISEASE; NERVE BLOCK; NONHUMAN; PAIN; PHOTODYNAMIC THERAPY; PHOTOTOXICITY; PIGMENT DISORDER; PRIORITY JOURNAL; PUSTULE; REVIEW; RISK ASSESSMENT; SCAR FORMATION; SKIN CANCER; SKIN INFECTION; SYSTEMATIC REVIEW; TECHNIQUE; TREATMENT OUTCOME;

HUMANS; PAIN; PHOTOCHEMOTHERAPY; SKIN NEOPLASMS;

EID: 79955601064     PISSN: 09054383     EISSN: 16000781     Source Type: Journal    
DOI: 10.1111/j.1600-0781.2010.00560.x     Document Type: Review

References (140)

1. Kennedy JC, Pottier RH, Pross DC. Photodynamic therapy with endogenous protoporphyrin IX: basic principles and present clinical experience. J Photochem Photobiol B 1990; 6: 143-148.
2. Morton CA, Brown SB, Collins S, et al. Guidelines for topical photodynamic therapy: report of a workshop of the British Photodermatology Group. Br J Dermatol 2002; 146: 552-567.
3. Morton CA, McKenna KE, Rhodes LE, British Assoc DT. Guidelines for topical photodynamic therapy: update. Br J Dermatol 2008; 159: 1245-1266.
4. Braathen LR, Szeimies RM, Basset-sequin N, et al. Guidelines on the use of photodynamic therapy for nonmelanoma skin cancer: an international consensus. J Am Acad Dermatol 2007; 56: 125-143.
5. Dragieva G, Hafner J, Dummer R, et al. Topical photodynamic therapy in the treatment of actinic keratoses and Bowen's disease in transplant recipients. Transplantation 2004; 77: 115-121.
6. Wennberg AM, Stenquist B, Stockfleth E, et al. Photodynamic therapy with methyl aminolevulinate for prevention of new skin lesions in transplant recipients: a randomized study. Transplantation 2008; 86: 423-429.
7. Wang I, Bendsoe N, Klinteberg CAF, et al. Photodynamic therapy vs. cryosurgery of basal cell carcinomas: results of a phase III clinical trial. Br J Dermatol 2001; 144: 832-840.
8. Clark C, Bryden A, Dawe R, Moseley H, Ferguson J, Ibbotson SH. Topical 5-aminolaevulinic acid photodynamic therapy for cutaneous lesions: outcome and comparison of light sources. Photoderm Photoimmun Photomed 2003; 19: 134-141.
9. Grapengiesser S, Gudmundsson O, Larko O, Ericson M, Rosen A, Wennberg AM. Pain caused by photodynamic therapy of skin cancer. Clin Exp Dermatol 2002; 27: 493-497.
10. Wennberg AM. Pain, pain relief and other practical issues in photodynamic therapy. Australas J Dermatol 2005; 46 (Suppl. 3): S4-S5.
11. Todd DJ. Erythropoietic protoporphyria. Br J Dermatol 1994; 131: 751-766.
12. Algermissen B, Osterloh D, Philipp CM, Berlien HP. Management of ALA-PDT induced pain sensations. Med Laser Appl 2003; 18: 57-64.
13. Valentine R, Ibbotson SH, Brown TA, Wood K, Moseley H. A quantitative comparison of 5-aminolaevulinic acid and methyl aminolevulinate-induced fluorescence, photobleaching and pain during photodynamic therapy. Photochem Photobiol 2011; 87: 242-249.
14. Gholam P, Denk K, Sehr T, Enk A, Hartmann M. Factors influencing pain intensity during topical photodynamic therapy of complete cosmetic units for actinic keratoses. J Am Acad Dermatol 2010; 63: 213-218.
15. Salim A, Leman JA, McColl JH, Chapman R, Morton CA. Randomized comparison of photodynamic therapy with topical 5-fluorouracil in Bowen's disease. Br J Dermatol 2003; 148: 539-543.
16. Morton C, Horn M, Leman J, et al. Comparison of topical methyl aminolevulinate photodynamic therapy with cryotherapy or fluorouracil for treatment of squamous cell carcinoma in situ - results of a multicenter randomized trial. Arch Dermatol 2006; 142: 729-735.
17. Morton CA, Whitehurst C, Moseley H, McColl JH, Moore JV, Mackie RV. Comparison of photodynamic therapy with cryotherapy in the treatment of Bowen's disease. Br J Dermatol 1996; 135: 766-771.
18. Basset-Seguin N, Ibbotson SH, Emtestam L, et al. Topical methyl aminolaevulinate photodynamic therapy versus cryotherapy for superficial basal cell carcinoma: a 5 year randomized trial. Eur J Dermatol 2008; 18: 547-553.
19. Waters AJ, Dawe RS, Ibbotson S. Factors associated with severe pain during ALA-PDT of skin lesions in Tayside: a retrospective review of nine years' data. Lasers Med Sci 2008; 23: 470-471.
20. Arits AHMM, Van de Weert MM, Nelemans PJ, Kelleners-Smeets NWJ. Pain during topical photodynamic therapy: uncomfortable and unpredictable. J Eur Acad Dermatol Venereol 2010; 24: 1452-1457.
21. Sandberg C, Stenquist B, Rosdahl I, et al. Important factors for pain during photodynamic therapy for actinic keratosis. Acta Derm Venereol 2006; 86: 404-408.
22. Moseley H, Ibbotson S, Woods J, et al. Clinical and research applications of photodynamic therapy in dermatology: experience of the Scottish PDT Centre. Lasers Surg Med 2006; 38: 403-416.
23. Rud E, Gederaas O, Hogset A, Berg K. 5-Aminolevulinic acid, but not 5-aminolevulinic acid esters, is transported into adenocarcinoma cells by system BETA transporters. Photochem Photobiol 2000; 71: 640-647.
24. Brooke RCC, Sinha A, Sidhu MK, et al. Histamine is released following aminolevulinic acid-photodynamic therapy of human skin and mediates an aminolevulinic acid dose-related immediate inflammatory response. J Invest Dermatol 2006; 126: 2296-2301.
25. Clark C, Dawe RS, Moseley H, Ferguson J, Ibbotson SH. The characteristics of erythema induced by topical 5-aminolaevulinic acid photodynamic therapy. Photoderm Photoimmunol Photomed 2004; 20: 105-107.
26. Sidhu MK, Brooke RCC, Clough GF, Rhodes LE. Nitric oxide and histamine are released during the skin inflammatory response to photodynamic therapy. Br J Dermatol 2005; 153(Suppl 1): 94, PD-8.
27. Warren CB, Karai LJ, Vidimos A, Maytin EV. Pain associated with aminolevulinic acid-photodynamic therapy of skin disease. J Am Acad Dermatol 2009; 61: 1033-1043.
28. Virgili A, Osti F, Maranini C, Corazza M. Photodynamic therapy: parameters predictive of pain. Br J Dermatol 2010; 162: 460-461.
29. Morton CA, Whitehurst C, McColl JH, Moore JV, MacKie RM. Photodynamic therapy for large or multiple patches of Bowen disease and basal cell carcinoma. Arch Dermatol 2001; 137: 319-324.
30. Hillemanns P, Untch M, Prove F, Baumgartner R, Hillemanns M, Korell M. Photodynamic therapy of vulvar lichen sclerosus with 5-aminolevulinic acid. Obstet Gynecol 1999; 93: 71-74.
31. Stender IM, Na RH, Fogh H, Gluud C, Wulf HC. Photodynamic therapy with 5-aminolaevulinic acid or placebo for recalcitrant foot and hand warts: randomised double-blind trial.
32. Stender IM, Borgbjerg FM, Villumsen J, Lock-Andersen J, Wulf HC. Pain induced by photodynamic therapy of warts. Photoderm Photoimmun Photomed 2006; 22: 304-309.
33. Robinson DJ, Collins P, Stringer MR, et al. Improved response of plaque psoriasis after multiple treatments with topical 5-aminolaevulinic acid photodynamic therapy. Acta Derm Venereol 1999; 79: 451-455.
34. Radakovic-Fijan S, Belcha-Thalhammer U, Schleyer V, et al. Topical aminolaevulinic acid-based photodynamic therapy as a treatment option for psoriasis? Results of a randomized, observer-blinded study. Br J Dermatol 2005; 152: 279-283.
35. Wiegell SR, Wulf HC. Photodynamic therapy of acne vulgaris using 5-aminolevulinic acid versus methyl aminolevulinate. J Am Acad Dermatol 2006; 64: 647-651.
36. Wiegell SR, Wulf HC. Photodynamic therapy of acne vulgaris using methyl aminolaevulinate: a blinded, randomized, controlled trial. Br J Dermatol 2006; 154: 969-976.
37. Wiegell SR, Stender IM, Na R, Wulf HC. Pain associated with photodynamic therapy using 5-aminolevulinic acid or 5-aminolevulinic acid methylester on tape-stripped normal skin. Arch Dermatol 2003; 139: 1173-1177.
38. Wiegell SR, Skiveren J, Philipsen PA, Wulf HC. Pain during photodynamic therapy is associated with protoporphyrin IX fluorescence and fluence rate. Br J Dermatol 2008; 158: 727-733.
39. Horfelt C, Funk J, Frohm-Nilsson M, Edstrom DW, Wennberg AM. Topical methyl aminolaevulinate photodynamic therapy for treatment of facial acne vulgaris: results of a randomized, controlled study. Br J Dermatol 2006; 155: 608-613.
40. Ericson MB, Sandberg C, Stenquist B, et al. Photodynamic therapy of actinic keratosis at varying fluence rates: assessment of photobleaching, pain and primary clinical outcome. Br J Dermatol 2004; 151: 1204-1212.
41. Lindeburg KE, Brogaard HM, Henriette MV, Jemec GBE. Pain and photodynamic therapy. Dermatology 2007; 215: 206-208.
42. Steinbauer JM, Schreml S, Babilas P, et al. Topical photodynamic therapy with porphyrin precursors - assessment of treatment-associated pain in a retrospective study. Photochem Photobiol Sci 2009; 8: 1111-1116.
43. Steinbauer J, Schremi S, Karrer S, et al. Phototoxic reactions in healthy volunteers following photodynamic therapy with methylaminolevulinate cream containing 5-aminolevulinic acid: a phase II, randomized study. Photoderm Photoimmunol Photomed 2009; 25: 270-275.
44. Moloney FJ, Collins P. Randomized, double-blind, prospective study to compare topical 5-aminolaevulinic acid methylester with topical 5-aminolaevulinic acid photodynamic therapy for extensive scalp actinic keratosis. Br J Dermatol 2007; 157: 87-91.
45. Kasche A, Luderschmidt S, Ring J, Hein R. Photodynamic therapy induces less pain in patients treated with methyl aminolevulinate compared to aminolevulinic acid. J Drugs Dermatol 2006; 5: 353-356.
46. Kuijpers DI, Thissen MR, Thissen CA, Neumann MH. Similar effectiveness of methyl aminolevulinate and 5-aminolevulinate in topical photodynamic therapy for nodular basal cell carcinoma. J Drugs Dermatol 2006; 5: 642-645.
47. Schleier P, Berndt A, Kolossa S, Zenk W, Hyckel P, Schultze-Mosgau S. Comparison of aminolevulinic acid (ALA)-thermogel-PDT with methyl-ALA-thermogel-PDT in basal cell carcinoma. Photodiagnosis Photodyn Ther 2007; 4: 197-201.
48. Kurwa HA, Yong-Gee SA, Seed PT, Markey AC, Barlow RJ. A randomized paired comparison of photodynamic therapy and topical 5-fluorouracil in the treatment of actinic keratoses. J Am Acad Dermatol 1999; 41: 414-418.
49. Pye A, Curnow A. Direct comparison of delta-aminolevulinic acid and methyl-aminolevulinate-derived protoporphyrin IX accumulations potentiated by desferrioxamine or the novel hydroxypyridinone iron chelator CP94 in cultured human cells. Photochem Photobiol 2007; 83: 766-773.
50. Hauschild A, Popp G, Stockfleth E, et al. Effective photodynamic therapy of actinic keratoses on the head and face with a novel, self-adhesive 5-aminolaevulinic acid patch. Exp Dermatol 2009; 18: 116-121.
51. Soler AM, Angell-Petersen E, Warloe T, et al. Photodynamic therapy of superficial basal cell carcinoma with 5-aminolevulinic acid with dimethylsulfoxide and ethylendiaminetetraacetic acid: a comparison of two light sources. Photochem Photobiol 2000; 71: 724-729.
52. Babilas P, Travnik R, Werner A, Landthaler M, Szeimies RM. Split-face-study using two different light sources for topical PDT of actinic keratoses: non-inferiority of the LED system. J Dtsch Dermatol Ges 2008; 6: 25-32.
53. Babilas P, Kohl E, Maisch T, et al. In vitro and in vivo comparison of two different light sources for topical photodynamic therapy. Br J Dermatol 2006; 154: 712-718.
54. Babilas P, Knobler R, Hummel S, et al. Variable pulsed light is less painful than light-emitting diodes for topical photodynamic therapy of actinic keratosis: a prospective randomized controlled trial. Br J Dermatol 2007; 157: 111-117.
55. Von Felbert V, Hoffmann G, Hoff-Lesch S, et al. Photodynamic therapy of multiple actinic keratoses: reduced pain through use of visible light plus water-filtered infrared A compared with light from light-emitting diodes. Br J Dermatol 2010; 163: 607-615.
56. Fritsch C, Stege H, Saalmann G, Goerz G, Ruzicka T, Krutmann J. Green light is effective and less painful than red light in photodynamic therapy of facial solar keratoses. Photoderm Photoimmunol Photomed 1997; 13: 181-185.
57. Morton CA, Whitehurst C, Moore JV, MacKie RM. Comparison of red and green light in the treatment of Bowen's disease by photodynamic therapy. Br J Dermatol 2000; 143: 767-772.
58. Mikolajewska P, Iani V, Juzeniene A, Moan J. Topical aminolaevulinic acid- and aminolaevulinic acid methyl ester-based photodynamic therapy with red and violet light: influence of wavelength on pain and erythema. Br J Dermatol 2009; 161: 1173-1179.
59. Radakovic-Fijan S, Blecha-Thathammer U, Kittler H, Honigsmann H, Tanew A. Efficacy of 3 different light doses in the treatment of actinic keratosis with 5-aminolevulinic acid photodynamic therapy: a randomized, observer-blinded, intrapatient, comparison study. J Am Acad Dermatol 2005; 53: 823-827.
60. Horfelt C, Stenquist B, Larko O, Faergemann J, Wennberg AM. Photodynamic therapy for acne vulgaris: a pilot study of the dose-response and mechanism of action. Acta Derm Venereol 2007; 87: 325-329.
61. Cottrell WJ, Paquette AD, Keymel KR, Foster TH, Oseroff AR. Irradiance-dependent photobleaching and pain in delta-aminolevulinic acid-photodynamic therapy of superficial basal cell carcinomas. Clin Cancer Res 2008; 14: 4475-4483.
62. Middelburg TA, van Zaane F, de Bruijn HS, et al. Fractionated illumination at low fluence rate photodynamic therapy in mice. Photochem Photobiol 2010; 86: 1140-1146.
63. Wiegell SR, Haedersdal M, Philipsen PA, Eriksen P, Enk CD, Wulf HC. Continuous activation of PpIX by daylight is as effective as and less painful than conventional photodynamic therapy for actinic keratoses; a randomized, controlled, single-blinded study. Br J Dermatol 2008; 158: 740-746.
64. Langmack K, Mehta R, Twyman P, Norris P. Topical photodynamic therapy at low fluence rates - theory and practice. J Photochem Photobiol B 2001; 60: 37-43.
65. Wiegell SR, Haedersdal M, Eriksen P, Wulf HC. Photodynamic therapy of actinic keratoses with 8% and 16% methyl aminolaevulinate and home-based daylight exposure: a double-blinded randomized clinical trial. Br J Dermatol 2009; 160: 1308-1314.
66. Attili SK, Lesar A, McNeill A, et al. An open pilot study of ambulatory photodynamic therapy using a wearable low-irradiance organic light-emitting diode light source in the treatment of nonmelanoma skin cancer. Br J Dermatol 2009; 161: 170-173.
67. Moseley H, Allen JW, Ibbotson S, et al. Ambulatory photodynamic therapy: a new concept in delivering photodynamic therapy. Br J Dermatol 2006; 154: 747-750.
68. Ibbotson SH. Irradiance is an important determinant of pain experienced during topical photodynamic therapy. J Am Acad Dermatol 2010 (in press).
69. de Haas ERM, de Vijlder HC, Sterenborg HJCM, Neumann HAM, Robinson DJ. Fractionated aminolevulinic acid-photodynamic therapy provides additional evidence for the use of PDT for non-melanoma skin cancer. J Eur Acad Dermatol Venereol 2008; 22: 426-430.
70. Wiegell SR, Haedersdal M, Wulf HC. Cold water and pauses in illumination reduces pain during photodynamic therapy: a randomized clinical study. Acta Derm Venereol 2009; 89: 145-149.
71. Pagliaro J, Elliott T, Bulsara M, King C, Vinciullo C. Cold air analgesia in photodynamic therapy of basal cell carcinomas as Bowen's disease: an effective addition to treatment: a pilot study. Dermatol Surg 2004; 30: 63-66.
72. Juzeniene A, Juzenas P, Ma LW, Iani V, Moan J. Effectiveness of different light sources for 5-aminlevulinic acid photodynamic therapy. Lasers Med Sci 2004; 19: 139-149.
73. Touma D, Yaar M, Whitehead S, Konnikov N, Gilchrist BA. A trial of short incubation, broad-area photodynamic therapy for facial actinic keratoses and diffuse photodamage. Arch Dermatol 2004; 140: 33-40.
74. Langan SM, Collins P. Randomized, double-blind, placebo-controlled prospective study of the efficacy of topical anaesthesia with a eutetic mixture of lignocaine 2.5% and prilocaine 2.5% for topical 5-aminolaevulinic acid-photodynamic therapy for extensive scalp actinic keratoses. Br J Dermatol 2006; 154: 146-149.
75. Holmes MV, Dawe RS, Ferguson J, Ibbotson SH. A randomized, double-blind, placebo-controlled study of the efficacy of tetracaine gel (Ametop((R)) for pain relief during topical photodynamic therapy. Br J Dermatol 2004; 150: 337-340.
76. Skiveren J, Haedersdal M, Philipsen PA, Wiegell SR, Wulf HC. Morphine gel 0.3% does not relieve pain during topical photodynamic therapy: a randomized, double-blind, placebo-controlled study. Acta Derm Venereol 2008; 86: 109-411.
77. Borelli C, Herzinger T, Merk K, et al. Effect of subcutaneous infiltration anaesthesia on pain in photodynamic therapy: a controlled open pilot trial. Dermatol Surg 2007; 33: 314-318.
78. Paoli J, Halldin C, Ericson MB, Wennberg AM. Nerve blocks provide effective pain relief during topical photodynamic therapy for extensive facial actinic keratoses. Clin Exp Dermatol 2008; 33: 559-564.
79. Halldin CB, Paoli J, Sandberg C, Gonzalez H, Wennberg AM. Nerve blocks enable adequate pain relief during topical photodynamic therapy of field cancerization on the forehead and scalp. Br J Dermatol 2009; 160: 795-800.
80. Halldin CB, Paoli J, Sandberg C, Ericson MB, Wennberg AM. Transcutaneous electrical nerve stimulation for pain relief during photodynamic therapy of actinic keratoses. Acta Derm Venereol 2008; 88: 311-313.
81. Kapur N, Kernland K, Braathen LR. Photodynamic therapy-induced pain: a patient-centred survey. Br J Dermatol 2003; 149: 47-48: p. 70.
82. Berking C, Herzinger T, Flaig MJ, Brenner M, Borelli C, Degitz K. The efficacy of photodynamic therapy in actinic cheilitis of the lower lip: a prospective study of 15 patients. Dermatol Surg 2007; 33: 825-830.
83. Lehmann P. Side effects of topical photodynamic therapy. Hautarzt 2007; 58: 597-603.
84. Wang I, Andersson-Engels S, Nilsson GE, Wardell K, Svanberg K. Superficial blood flow following photodynamic therapy of malignant non-melanoma skin tumours measured by laser Doppler perfusion imaging. Br J Dermatol 1997; 136: 184-189.
85. Toll A, Parera ME, Velez M, Pujol RM. Photodynamic therapy with methyl aminolevulinate induces phototoxic reactions on areas of the nose adjacent to basal cell carcinomas and actinic keratoses. Dermatol Surg 2008; 34: 1145-1148.
86. Tsoukas MM, Lin GC, Lee MS, Anderson RR, Kollias N. Predictive dosimetry for threshold phototoxicity in photodynamic therapy on normal skin: red wavelengths produce more extensive damage than blue at equal threshold doses. J Invest Dermatol 1997; 108: 501-505.
87. Salomon D, Barges J, Glanzmann T, Wagnieres G. Correlations between tissular effects, PPIX fluorescence and the pain induced by PDT on normal skin. J Invest Dermatol 2007; 127(Suppl 2): S47, 277.
88. Casas A, Fukuda H, Di Venosa G, Batlle A. Photosensitization and mechanism of cytotoxicity induced by the use of ALA derivatives in photodynamic therapy. Br J Cancer 2001; 85: 279-284.
89. Angell-Petersen E, Christensen C, Muller CR, Warloe T. Phototoxic reaction and porphyrin fluorescence in skin after topical application of methyl aminolaevulinate. Br J Dermatol 2007; 156: 301-307.
90. Tyrrell JS, Campbell SM, Curnow A. The relationship between protoporphyrin IX photobleaching during real-time dermatological methyl-aminolevulinate photodynamic therapy (MAL-PDT) and subsequent clinical outcome. Lasers Surg Med 2010; 42: 613-619.
91. Ibbotson SH, Jong C, Lesar A, et al. Characteristics of 5-aminolaevulinic acid-induced protoporphyrin IX fluorescence in human skin in vivo. Photoderm Photoimmun Photomed 2006; 22: 105-110.
92. Gerscher S, Connelly JP, Griffiths J, et al. Comparison of the pharmacokinetics and phototoxicity of protoporphyrin IX metabolized from 5-aminolevulinic acid and two derivatives in human skin in vivo. Photochem Photobiol 2000; 72: 569-574.
93. Gerscher S, Connelly JP, Beijersbergen van Henegouwen GM, MacRobert AJ, Watt P, Rhodes LE. A quantitative assessment of protoporphyrin IX metabolism and phototoxicity in human skin following dose-controlled delivery of the prodrugs 5-aminolaevulinic acid and 5-aminolaevulinic acid-n-pentylester. Br J Dermatol 2001; 144: 983-990.
94. Bourre L, Giuntini F, Eggleston IM, Wilson M, MacRobert AJ. 5-aminolaevulinic acid peptide prodrugs enhance photosensitization for photodynamic therapy. Mol Cancer Ther 2008; 7: 1720-1729.
95. Juzeniene A, Nielsen KP, Zhaob L, et al. Changes in human skin after topical PDT with hexyl aminolevulinate. Photodiagnosis Photodyn Ther 2008; 5: 176-181.
96. Pollock B, Turner D, Stringer MR, et al. Topical aminolaevulinic acid-photodynamic therapy for the treatment of acne vulgaris: a study of clinical efficacy and mechanism of action. Br J Dermatol 2004; 151: 616-622.
97. Hongcharu W, Taylor CR, Chang Y, Aghassi D, Suthamjariya K, Anderson RR. Topical ALA-photodynamic therapy for the treatment of acne vulgaris. J Invest Dermatol 2000; 115: 183-192.
98. Misra A, Maybury K, Eltigani TA. Late erythema after photodynamic therapy to the face. Plast Reconstr Surg 2006; 117: 2522-2523.
99. Kerr AC, Ferguson J, Ibbotson SH. Acute phototoxicity with urticarial features during topical 5-aminolaevulinic acid photodynamic therapy. Clin Exp Dermatol 2007; 32: 201-202.
100. Kaae J, Philipsen PA, Haedersdal M, Wulf HC. Immediate whealing urticaria in red light exposed areas during photodynamic therapy. Acta Derm Venereol 2008; 88: 480-483.
101. Yokoyama S, Nakano H, Nishizawa A, Kaneko T, Harada K, Hanada K. A case of photocontact urticaria induced by photodynamic therapy with topical 5-aminolaevulinic acid. J Dermatol 2005; 32: 843-847.
102. Yung A, Stables GI, Fernandez C, Williams J, Bojar RA, Goulden V. Microbiological effect of photodynamic therapy (PDT) in healthy volunteers: a comparative study using methyl aminolaevulinate and hexyl aminolaevulinate cream. Clin Exp Dermatol 2007; 32: 716-721.
103. Dai T, Huang YY, Hamblin MR. Photodynamic therapy for localized infections-State of the art. Photodiagnosis Photodyn Ther 2009; 6: 170-188.
104. Wolfe CM, Hatfield K, Cognetta AB. Cellulitis as a postprocedural complication of topical 5-aminolevulinic acid photodynamic therapy in the treatment of actinic keratosis. J Drugs Dermatol 2007; 6: 544-548.
105. Guarneri C, Vaccaro M. Erosive pustular dermatosis of the scalp following topical methylaminolaevulinate photodynamic therapy. J Am Acad Dermatol 2009; 60: 521-522.
106. Meyer T, Lopez-Navarro N, Herrera-Acosta E, Jose A, Herrera E. Erosive pustular dermatosis of the scalp: a successful treatment with photodynamic therapy. Photoderm Photoimmunol Photomed 2010; 26: 44-45.
107. Barnadas MA, Gilaberte M, Pujol R, Agusti M, Gelpi C, Alomar A. Bullous pemphigoid in a patient with psoriasis during the course of PUVA therapy: study by ELISA test. Int J Dermatol 2006; 45: 1089-1092.
108. Hayami J, Okamoto H, Sugihara A, Horio T. Immunosuppressive effects of photodynamic therapy by topical aminolevulinic acid. J Dermatol 2007; 34: 320-327.
109. Kyagova AA, Mansurova GV, Kozir LA, et al. Systemic suppression of the contact hypersensitivity by the products of protoporphyrin IX photooxidation. Photochem Photobiol 2005; 81: 1380-1385.
110. Matthews YJ, Damian DL. Topical photodynamic therapy is immunosuppressive in humans. Br J Dermatol 2010; 162: 637-641.
111. Dragieva G, Prinz BM, Hafner J, et al. A randomized controlled clinical trial of topical photodynamic therapy with methyl aminolaevulinate in the treatment of actinic keratoses in transplant recipients. Br J Dermatol 2004; 151: 196-200.
112. de Graaf YGL, Kennedy C, Wolterbeek R, Collen AFS, Willemze R, Bavinck JNB. Photodynamic therapy does not prevent cutaneous squamous-cell carcinoma in organ-transplant recipients: results of a randomized-controlled trial. J Invest Dermatol 2006; 126: 569-574.
113. Gniazdowska B, Rueff F, Hillemanns P, Przybilla B. Allergic contact dermatitis from delta-aminolevulinic acid used for photodynamic therapy. Contact Dermatitis 1998; 38: 348-349.
114. Wulf HC, Philipsen P. Allergic contact dermatitis to 5-aminolaevulinic acid methylester but not to 5-aminolaevulinic acid after photodynamic therapy. Br J Dermatol 2004; 150: 143-145.
115. Harries MJ, Street G, Gilmour E, Rhodes LE, Beck MH. Allergic contact dermatitis to methyl aminolevulinate (Metvix) cream used in photodynamic therapy. Photoderm Photoimmunol Photomed 2007; 23: 35-36.
116. Hohwy T, Andersen KE, Solvsten H, Sommerlund M. Allergic contact dermatitis to methyl aminolevulinate after photodynamic therapy in 9 patients. Contact Dermatitis 2007; 57: 321-323.
117. Korshoj S, Solvsten H, Erlandsen M, Sommerlund M. Frequency of sensitization to methyl aminolaevulinate after photodynamic therapy. Contact Dermatitis 2009; 60: 320-324.
118. Fink-Puches R, Soyer HP, Hofer A, Kerl H, Wolf P. Long-term follow-up and histological changes of superficial nonmelanoma skin cancers treated with topical delta-aminolevulinic acid photodynamic therapy. Arch Dermatol 1998; 134: 821-826.
119. Ghaffar SA, Clements SE, Lear JT. Epidermoid cysts mimicking recurrence of superficial basal cell carcinoma following photodynamic therapy. Clin Exp Dermatol 2007; 32: 223-224.
120. Hanneken S, Wessendorf U, Neumann NJ. Photodynamic onycholysis: first report of photo-onycholysis after photodynamic therapy. Clin Exp Dermatol 2008; 33: 659-660.
121. Schroeter CA, Kaas L, Waterval JJ, Bos PM, Neumann HAM. Successful treatment of periungual warts using photodynamic therapy: a pilot study. J Eur Acad Dermatol Venereol 2007; 21: 1170-1174.
122. Baran R, Juhlin L. Drug-induced photo-onycholysis - 3 subtypes identified in a study of 15 cases. J Am Acad Dermatol 1987; 17: 1012-1016.
123. Itoh Y, Ninomiya Y, Tajima S, Ishibashi A. Photodynamic therapy of acne vulgaris with topical delta-aminolaevulinic acid and incoherent light in Japanese patients. Br J Dermatol 2001; 144: 575-579.
124. Monfrecola G, Procaccini EM, D'Onofrio D, et al. Hyperpigmentation induced by topical 5-aminolaevulinic acid plus visible light. J Photochem Photobiol B 2002; 68: 147-155.
125. Monfrecola G, D'Anna F, Delfino M. Topical hematoporphyrin plus UVA for treatment of alopecia areata. Photodermatology 1987; 4: 305-306.
126. Bissonnette R, Shapiro J, Zeng H, McLean DI, Lui H. Topical photodynamic therapy with e-aminolaevulinic acid does not induce hair regrowth in patients with extensive alopecia areata. Br J Dermatol 2000; 143: 1032-1035.
127. Fernandez-Guarino M, Harto A, Garcia-Morales I, Perez-Garcia B, Arrazola JM, Jaen P. Failure to treat alopecia areata with photodynamic therapy. Clin Exp Dermatol 2008; 33: 585-587.
128. Morokuma Y, Yamazaki M, Maeda T, et al. Hair growth stimulatory effect by a combination of 5-aminolevulinic acid and iron ion. Int J Dermatol 2008; 47: 1298-1303.
129. Wanner M. Laser hair removal. Dermatol Ther 2005; 18: 209-216.
130. Dierickx CC, Grossman MC. Laser hair removal. In: Dover JS, Goldberg DJ, eds. Laser and lights; Vol. 2. Philadelphia: Elsevier Saunders, 2005; 61-76.
131. Chu ESM, Wu RWK, Yow CMN, Wong TKS, Chen JY. The cytotoxic and genotoxic potential of 5-aminolevulinic acid on lymphocytes: a comet assay study. Cancer Chemother Pharmacol 2006; 58: 408-414.
132. Calzavara-Pinton PG, Venturini M, Sala R. Photodynamic therapy: update 2006 - part 1: photochemistry and photobiology. J Eur Acad Dermatol Venereol 2007; 21: 293-302.
133. Chung WY, Lee JM, Lee JW, Surh YJ, Park KK. Protective effects of hemin and tetrakis (4-benzoic acid) porphyrin on bacterial mutagenesis and mouse skin carcinogenesis induced by 7, 12-dimethylbenz(a)anthracene. Mutat Res 2000; 472: 139-145.
134. Finlan LE, Kernohan NM, Thomson G, Beattie PE, Hupp TR, Ibbotson SH. Differential effects of 5-aminolaevulinic acid photodynamic therapy and psoralen plus ultraviolet A therapy on p53 phosphorylation in normal human skin in vivo. Br J Dermatol 2005; 153: 1001-1010.
135. Stender IM, BechThomsen N, Poulsen T, Wulf HC. Photodynamic therapy with topical delta-aminolevulinic acid delays UV photocarcinogenesis in hairless mice. Photochem Photobiol 1997; 66: 493-496.
136. Fuchs J, Weber S, Kaufmann R. Genotoxic potential of porphyrin type photosensitizers with particular emphasis on 5-aminolevulinic acid: implications for clinical photodynamic therapy. Free Radic Biol Med 2000; 28: 537-548.
137. Wolf P, FinkPuches R, ReimannWeber A, Kerl H. Development of malignant melanoma after repeated topical photodynamic therapy with 5-aminolevulinic acid at the exposed site. Dermatology 1997; 194: 53-54.
138. Maydan E, Nootheti PK, Goldman MP. Case reports: development of a keratoacanthoma after topical photodynamic therapy with 5-aminolevulinic acid. J Drugs Dermatol 2006; 5: 804-806.
139. Varma S, Holt PJA, Anstey AV. Erythroplasia of Queyrat treated by topical aminolaevulinic acid photodynamic therapy: a cautionary tale. Br J Dermatol 2000; 142: 825-826.
140. Attili S, Ibbotson S, Fleming C. Role of non-surgical therapies in the management of periocular basal cell carcinoma and squamous intraepidermal carcinoma. Dermatol Surg 2010 (submitted).